EAU 2017: Long Term (5 Year) Results From The Largest, Prospective, Randomized, Controlled Study Of The Minimally Invasive Prostatic Urethral Lift (Pul)

London, England (UroToday.com) Benign prostatic hyperplasia (BPH) is a common, age-related condition that clinically manifests as lower-urinary tract symptoms (LUTS). LUTS associated with BPH significantly increase with age, as does the need for intervention. Quality of life of patients with LUTS is significantly affected by these symptoms.

EAU 2017: Predictive Factors Of Insertion Failure Of Ureteral Access Sheath For Flexible Ureteroscopy: A Study Of 594 Procedures

London, England (UroToday.com) Ureteral access sheaths (UAS) are commonly used during retrograde and antegrade renal procedures to facility the easy passage of ureteroscope to into the collecting system.

EAU 2017: Impact Of Preoperative A-adrenergic Antagonists On Ureteral Access Sheath Insertion Force And The Upper Limit Of Force To Avoid Ureteral Mucosal Injury: A Randomized Controlled Study

London, England (UroToday.com) With the dramatic increase in incidence and prevalence of urolithiasis for the past two decades, treatment options have evolved from open surgery to percutaneous and now ureteroscopy (URS) is commonly used modality when feasible.

EAU 2017: Perioperative chemotherapy does not improve disease free survival in upper tract urothelial carcinoma: a population based analysis

London, England (UroToday.com) Upper tract urothelial carcinoma (UTUC) is a rare disease, accounting for less than 5% of all urothelial cancers and with a peak incidence in the 8th and 9th decade. The role of perioperative chemotherapy remains poorly defined. Current practice in UTUC is derived from evidence related to muscle-invasive bladder cancer, where it has been shown to have a positive effect on cancer specific survival (CSS).

EAU 2017: State-of-the-art lecture Levels of competence in mpMRI reporting

London, England (UroToday.com) Dr. Puech gave a talk on multiparametric MRI (mpMRI) reporting.
We as urologist expect several things from the radiologist reading and reporting mpMRI of the prostate. The mpMRI should give good quality results and enable us to locate suspicious lesions with high probability of being significant prostate cancer. The images should allow us to plan targeted biopsies, treatment and adequate follow-up. The results should be reproducible and standardized. Finally, the mpMRI produced report will hopefully allow us to convey the results to the patients in a simple manner as well.

EAU 2017: State-of-the-art lecture : What do urologists need to know about mpMRI targeted biopsy?

London, England (UroToday.com) Dr. Boxler presented his opinion on what urologists need to know about multiparametric MRI (mpMRI) targeted biopsy.

EAU 2017: Discussant: Is PIRADS 2.0 standardized enough?

London, England (UroToday.com) Dr. Polascik gave a presentation on PIRADS ver. 2 outlining differences from ver. 1, limitations and possible solutions. Several studies were initially presented, comparing performance of PIRADS 1 to PIRADS 2.

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.